April 25th 2024
In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Statins Can Cut Heart Attacks in Moderate-Risk Patients, Study Finds
April 2nd 2016Results from the HOPE-3 trial, presented on the opening day of the 65th Scientific Session of the American College of Cardiology, suggest cholesterol-lowering statins could have preventive benefits in broader groups of patients than previously thought.
Read More
Fewer Amputations, Hospital Deaths as Treatment Switches for Patients with Critical Limb Ischemia
March 21st 2016The study from researchers at Cleveland Clinic found that during the years before full implementation of the Affordable Care Act, a shift in treatment methods for patients with a painful condition was associated with fewer amputations and deaths. But large disparities remain.
Read More
Inpatient and 90-Day Postdischarge Outcomes in Cardiac Surgery
Coronary artery bypass grafting and cardiac valve surgery have dramatically different risk-adjusted outcomes over the 90 days following discharge, and demonstrate the opportunity for care improvement.
Read More
CVS Strikes Deal for Repatha Only; 18,000 Enroll in Long-term Praluent CV Outcomes Trial
November 24th 2015Terms of the deal with the second-largest pharmacy benefit manager were not disclosed. Pricing for the PCSK9 inhibitor class has been a source of controversy since the cholesterol-fighting drugs were approved this summer.
Read More
Medication Adherence and Healthcare Disparities: Impact of Statin Co-Payment Reduction
This study examined patterns of medication adherence after a reduction in medication co-payment amount among privately insured patients living in racially diverse neighborhoods.
Read More
So Praluent Is Approved. The Question Now Is, Who Gets It?
July 27th 2015Health plans and pharmacy benefits managers are expected to scrutinize the FDA approval to ensure that only those patients who truly need the drug get it.Drugmakers say discounts will cause the price to fall below the $14,600 annual wholesale price listed.
Read More
Newer Cholesterol Guidelines Prove Beneficial and Cost-Effective
July 14th 2015The American College of Cardiology and the American Heart Association's release of recommendations for statin treatment in the prevention of cardiovascular disease (CVD) in 2013 have now proven both cost-effective and accurate in identifying CVD risk.
Read More
ELIXA Trial Results Find No Cardiac Risk, Benefit for Lixisenatide
June 9th 2015Results are the first from a cardiovascular safety trial in the GLP-1 agonist class. A commentator at the 75th Scientific Sessions of the American Diabetes Association asked whether the FDA-mandated studies are giving physicians the right information.
Read More
Sitagliptin Does Not Cause Adverse Cardiovascular Effects, TECOS Trial Finds
June 9th 2015The long-awaited results, presented Monday at the 75th Scientific Sessions of the American Diabetes Association, are expected to strengthen sitagliptin's position against its competitors in the DPP-4 inhibitor class.
Read More
5-Year Follow-up After Lifestyle Intervention Examines Cardiovascular Effects of Keeping Weight Off
June 7th 2015Osama Hamdy, MD, PhD, and other researchers at Joslin Diabetes Center showed that patients with obesity and diabetes who lost at least 7% of their weight the first year stood a better chance of keeping it off.
Read More
New Study Helps Explain Patient Nonadherence to Cardiovascular Disease Medications
June 5th 2015Researchers traced a patient's nonadherence to cardiovascular disease (CVD)-related medications to the number of medications an individual is prescribed as well as at what times these medications need to be taken. While prescribed CVD medications control associated risk factors such as hypertension and hyperlipidemia, more than half of the patients on a prescribed medication plan fail to take their prescriptions as needed.
Read More